augidacla 60 mg 28 tablets

augidacla tablets are an antiviral medication containing the active ingredient Daclatasvir. It is used as part of treatment protocols for certain cases of chronic viral infections, particularly those associated with chronic Hepatitis C virus (HCV) infection.

The medication helps reduce viral replication within the body and supports achieving improved treatment outcomes when used in combination with appropriate antiviral therapies. It is prescribed by a physician based on the patient's medical condition and the results of laboratory tests performed before treatment initiation.

Composition of augidacla

• Daclatasvir.

Strength and Dosage Form of augidacla

augidacla is available as film-coated tablets containing 60 mg of Daclatasvir. Each package contains 28 tablets.

The medication should be used according to the physician’s instructions and based on the patient's condition and therapeutic requirements.

Indications of augidacla

• Treatment of certain cases of chronic Hepatitis C infection.

• Helping reduce the viral load within the body.

• Use as part of combination antiviral treatment regimens.

• Supporting the achievement of a sustained virologic response in suitable patients.

• Helping reduce the progression of complications associated with chronic viral infections.

Dosage of augidacla

The usual dose is 60 mg once daily. The medication may be taken with or without food according to the physician’s instructions. It is recommended to take the tablet at the same time every day to help achieve optimal therapeutic effectiveness.

The dose should not be changed, and treatment should not be discontinued unless directed by a healthcare professional. If a dose is missed, the patient should consult a physician or pharmacist for appropriate guidance without affecting the treatment plan.

Side Effects of augidacla

• Headache.

• Fatigue and tiredness.

• Nausea.

• Sleep disturbances.

• Dizziness.

• Decreased appetite in some cases.

• Mild gastrointestinal disturbances.

Contraindications of augidacla

augidacla should not be used in patients with known hypersensitivity to Daclatasvir or any of the product's ingredients.

The medication should also be avoided with certain drugs that may significantly affect its effectiveness unless specifically approved by a physician. Patients should inform their healthcare provider about all medications and dietary supplements they are taking before starting treatment to avoid potential drug interactions.

Alternatives to augidacla

• Daclavirocyrl.

• Daclavirdin.

• Zetaciver.

• Andodaclata.

How to Use augidacla Correctly

Patients should take the prescribed dose every day and at the same time daily to help achieve the best possible treatment outcomes. Treatment should not be stopped, and the dosage should not be modified without consulting a physician.

Regular medical follow-up and laboratory testing are important to monitor the condition and evaluate the response to treatment. Patients should inform their physician if any unusual symptoms occur and should adhere to the complete prescribed treatment plan according to medical recommendations.

Storage Conditions

• Store at room temperature.

• Keep away from moisture and excessive heat.

• Store in the original package.

• Keep out of the reach of children.

• Do not use after the expiration date.